Compare Kohl's Corporation (KSS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Sana Biotechnology Inc — how do they compare? Kohl's Corporation trades at $19.01 (market cap $2.06B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Kohl's Corporation is far larger — about 2.3× Sana Biotechnology Inc's market cap, and Kohl's Corporation pays a 2.76% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KSS | SANA | |
|---|---|---|
Market Cap | $2.06B | $879.40M |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $5.92 |
52-Week Low | $10.73 | $2.68 |
Enterprise Value | $8.16B | $853.59M |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $18.12, up 4.74% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $16.75. The stock shows low valuation multiples with a P/E of 7.38 and P/S of 0.13, while recent earnings have beaten expectations. Revenue has declined from $19.4B in 2022 to $16.2B in 2025, but net income improved to $109M. The company is focusing on proprietary brands and operational improvements under new leadership.
The outlook suggests a turnaround opportunity with attractive valuations and recent operational progress, but risks include persistent revenue declines and competitive pressures. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Upside depends on successful execution of the company's revitalization strategy amid a challenging retail environment.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
